NCT01899859: Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis |
|
|
| Completed | 1 | 31 | US | GR-MD-02, galactoarabino-rhamnogalaturonate, Placebo | Galectin Therapeutics Inc. | Non-Alcoholic Steatohepatitis (NASH) | 02/15 | 02/15 | | |
